Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous iPSC-RPE for Macular Degeneration
NCT05445063Phase 1Recruiting
- Sponsor
- Beijing Tongren Hospital
- Start
- Aug 2022
- Primary completion
- Jul 2026
- Modality
- Patient-derived iPSCs, Allogeneic iPSCs
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of autologous ipsc-derived rpe in Age-related macular degeneration (AMD), sponsored by Beijing Tongren Hospital. Primary endpoint: Safety measure at 12 months. Started Aug 2022; status: recruiting.
02
Drugs
autologous ipsc-derived rpe
03
Conditions
Age-related macular degeneration (AMD)
Beyond the preview
Go deeper on NCT05445063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05445063.